EFFECTIVENESS OF RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD): REAL WORLD OUTCOMES FROM THE SECOND INTERIM ANALYSIS OF THE LUMINOUS STUDY

被引：0
|
作者：
Gilhotra, Jagjit Singh [1 ,2 ]
Mitchell, Paul [3 ]
Vote, Brendan [4 ]
Lacey, Sue
机构：
[1] Univ Adelaide, Dept Ophthalmol, Adelaide, SA, Australia
[2] Queen Elizabeth Hosp, Dept Ophthalmol, Adelaide, SA, Australia
[3] Univ Sydney, Dept Ophthalmol & Westmead Millennium Inst, Ctr Vis Res, Sydney, NSW 2006, Australia
[4] Launceston Eye Inst, Launceston, Tas, Australia
[5] Novartis Pharma AG, Basel, Switzerland
来源：
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY | 2015年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
110
引用
收藏
页码：119 / 120
页数：2
相关论文
共 50 条
  • [41] Neovascular Age-Related Macular Degeneration (nAMD): A Review of Emerging Treatment Options
    Tan, Colin S.
    Ngo, Wei Kiong
    Chay, Isaac W.
    Ting, Dominic S.
    Sadda, SriniVas R.
    [J]. CLINICAL OPHTHALMOLOGY, 2022, 16 : 917 - 933
  • [42] Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration
    Abouammoh, Marwan
    Sharma, Sanjay
    [J]. CURRENT OPINION IN OPHTHALMOLOGY, 2011, 22 (03) : 152 - 158
  • [43] Cost-Effectiveness of Ranibizumab Compared with Photodynamic Treatment of Neovascular Age-Related Macular Degeneration
    Javier Hernandez-Pastor, Luis
    Ortega, Ana
    Garcia-Layana, Alfredo
    Giraldez, Joaquin
    [J]. CLINICAL THERAPEUTICS, 2008, 30 (12) : 2436 - 2451
  • [44] NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) IN ITALY: A SOCIAL COST ANALYSIS
    Fasci, A.
    Pradelli, L.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S261 - S261
  • [45] Real world outcomes with intravitreal ranibizumab in neovascular age related macular degeneration (nAMD) using a monitor-and-extend regimen in stable patients
    Varma, D.
    Sandhu, J.
    Steel, D. H. W.
    Kotagiri, A.
    Habib, M.
    Sandinha, T.
    Smith, J.
    [J]. EYE, 2017, 31 : S10 - S11
  • [46] Real-World Outcomes of Faricimab Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
    Quah, Nicole Q. X.
    Javed, Khawaja Muhammad Ammar Ali
    Arbi, Lamees
    Hanumunthadu, Daren
    [J]. CLINICAL OPHTHALMOLOGY, 2024, 18 : 1479 - 1490
  • [47] Phase 3 evaluation of the efficacy and safety of abicipar compared with ranibizumab for treatment of neovascular age-related macular degeneration (nAMD)
    Kunimoto, Derek
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [48] Ranibizumab in patients with neovascular age-related macular degeneration in real-world clinical settings in France: 1-year data from the LUMINOUS™ study
    Capuano, Vittorio
    Oubraham-Mebroukine, Hassiba
    Wolff, Benjamin
    Cohen, Salomon Y.
    Garcher, Catherine P.
    Korobelnik, Jean-Francois
    Tadayoni, Ramin
    Delhay, Christian
    Derveloy, Audrey
    Souied, Eric H.
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [49] Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
    Yanagi, Yasuo
    Takahashi, Kanji
    Iida, Tomohiro
    Gomi, Fumi
    Morii, Junko
    Kunikane, Eriko
    Sakamoto, Taiji
    [J]. OPHTHALMOLOGY AND THERAPY, 2023, 12 (04) : 2005 - 2021
  • [50] Six-year outcomes in neovascular age-related macular degeneration with ranibizumab
    Jacob, Julie
    Brie, Heidi
    Leys, Anita
    Levecq, Laurent
    Mergaerts, Filip
    Denhaerynck, Kris
    Vancayzeele, Stefaan
    Van Craeyveld, Eline
    Abraham, Ivo
    MacDonald, Karen
    [J]. INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2017, 10 (01) : 81 - 90
12345